Paul Hallenbeck

Paul Hallenbeck has extensive work experience in the biotechnology and pharmaceutical industries. Paul is the founder and CEO of Seneca Therapeutics, Inc. and also served as the company's president and chief scientific officer. Prior to that, they were an executive director at Premier Research, where they focused on drug development strategy in the field of oncology. Paul has also held leadership positions at Hangzhou Bensheng Pharmaceuticals, Synbody Biotechnology, Inc., NISCO International, Inc., Neotropix Inc, and Novartis. Throughout their career, they have been involved in various aspects of research and development, including preclinical testing, clinical trial development, and FDA regulatory filing. Paul has a strong background in oncology therapeutics and has worked on the development of novel small molecule and antibody-based compounds for the treatment of cancer.

Paul Hallenbeck earned a Doctor of Philosophy (Ph.D.) degree in Microbiology, General from the University of Illinois Urbana-Champaign. Paul attended the university from 1982 to 1988. Prior to this, they obtained a Bachelor of Science (B.Sc.) degree in Chemistry from Siena College. However, the specific details regarding the duration of their time at Siena College are unknown.